Concentrix (NASDAQ:CNXC) Issues FY 2026 Earnings Guidance

Concentrix (NASDAQ:CNXC) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 11.480-12.070 for the period, compared to the consensus EPS estimate of 11.600. The company issued revenue guidance of $10.0 billion-$10.2 billion, compared to the consensus revenue estimate of $10.1 billion. Concentrix also updated its Q2 2026 guidance to 2.570-2.690 EPS.

Analysts Set New Price Targets

Several brokerages have issued reports on CNXC. Weiss Ratings downgraded Concentrix from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, January 29th. Wall Street Zen downgraded Concentrix from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Robert W. Baird lowered their price target on Concentrix from $52.00 to $40.00 and set an “outperform” rating for the company in a report on Wednesday, March 25th. Canaccord Genuity Group reduced their price objective on Concentrix from $80.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th. Finally, Barrington Research reduced their price objective on Concentrix from $62.00 to $38.00 and set an “outperform” rating for the company in a research report on Wednesday, March 25th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $48.50.

Concentrix Trading Up 1.4%

CNXC traded up $0.38 during midday trading on Thursday, hitting $28.11. 500,105 shares of the company were exchanged, compared to its average volume of 1,505,561. The firm has a market capitalization of $1.73 billion, a P/E ratio of -1.30, a P/E/G ratio of 0.34 and a beta of 0.50. Concentrix has a 1-year low of $24.27 and a 1-year high of $62.14. The firm’s 50 day moving average price is $32.10 and its 200-day moving average price is $38.33. The company has a quick ratio of 1.40, a current ratio of 1.18 and a debt-to-equity ratio of 1.43.

Concentrix (NASDAQ:CNXC) last issued its earnings results on Tuesday, March 24th. The company reported $2.61 EPS for the quarter, missing analysts’ consensus estimates of $2.65 by ($0.04). The firm had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.49 billion. Concentrix had a negative net margin of 13.35% and a positive return on equity of 17.80%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.79 earnings per share. As a group, equities analysts forecast that Concentrix will post 10.11 EPS for the current fiscal year.

Concentrix Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 5th. Shareholders of record on Friday, April 24th will be given a dividend of $0.36 per share. The ex-dividend date is Friday, April 24th. This represents a $1.44 annualized dividend and a dividend yield of 5.1%. Concentrix’s dividend payout ratio is currently -6.68%.

Insider Activity

In other news, CEO Christopher A. Caldwell bought 1,000 shares of Concentrix stock in a transaction that occurred on Thursday, January 29th. The shares were acquired at an average price of $37.07 per share, with a total value of $37,070.00. Following the completion of the purchase, the chief executive officer directly owned 362,075 shares in the company, valued at $13,422,120.25. The trade was a 0.28% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CNXC. Royal Bank of Canada grew its stake in shares of Concentrix by 9.5% during the first quarter. Royal Bank of Canada now owns 47,501 shares of the company’s stock valued at $2,643,000 after buying an additional 4,133 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Concentrix by 75.1% during the first quarter. Goldman Sachs Group Inc. now owns 423,287 shares of the company’s stock valued at $23,552,000 after buying an additional 181,546 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Concentrix by 17.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 146,515 shares of the company’s stock valued at $8,152,000 after buying an additional 21,746 shares during the last quarter. Focus Partners Wealth bought a new position in shares of Concentrix during the first quarter valued at about $781,000. Finally, Geneos Wealth Management Inc. grew its stake in shares of Concentrix by 532.7% during the first quarter. Geneos Wealth Management Inc. now owns 620 shares of the company’s stock valued at $34,000 after buying an additional 522 shares during the last quarter. 90.34% of the stock is owned by institutional investors.

About Concentrix

Concentrix Inc (NASDAQ: CNXC) is a global business services company specializing in customer engagement solutions and technology‐driven business process outsourcing. The firm’s offerings encompass customer care delivered across voice and digital channels, back‐office processing, analytics and consulting, and automated workflow management. By integrating proprietary platforms, strategic partnerships and advanced automation, Concentrix helps clients enhance customer experiences and streamline operations.

Its capabilities extend to digital marketing and technology implementation, leveraging artificial intelligence, machine learning and data analytics to optimize customer journeys.